Ganciclovir (G) pharmacokinetics in renal transplant patients (RTR) with cytomegalovirus (CMV) infection.
ASN 30th Annual Meeting, San Antonio
J Am Soc Nephrol (Sep) 8:702A 1997
Ganciclovir is available intravenously and orally for the treatment of CMV infection in immunocompromized patients. Saigal and colleagues demonstrated that intravenous dosing of ganciclovir resulted in plasma concentrations above the IC50 for susceptible strains for most of the dosing interval, while standard oral doses resulted in levels far below the IC50.
Comment: This study raises the serious concern that oral therapy with ganciclovir would be ineffective, could lead to relapse after initial intravenous therapy, and result in the promotion of resistant CMV strains. The results may explain failure of oral ganciclovir to prevent recurrent CMV infection. (George R. Aronoff, M.D., University of Louisville, Kentucky)
To go back use the BACK button on your browser. Otherwise click on the desired link to this article below:
ASN 30th Annual Meeting, San Antonio
Transplant : Transplantation